[Effects of ulinastatin on experimental arthritis].
Effects of the urinary enzyme inhibitor ulinastatin on experimental arthritis were investigated. Ulinastatin at the dose of 30,000 units/kg/day, i.v., significantly restored the swelling of hind paw, inflammatory score and bone damage in adjuvant arthritic rats. Intraarticular administration of ulinastatin at 3000 units/site x 3, significantly suppressed the articular swelling and the elevated inflammatory parameters in the synovial fluid of carrageenin-induced arthritic rabbits. Moreover, ulinastatin at the dose of 50000 units/kg/day, i.v., significantly prevented the elevation of serum rheumatoid factor and articular lesions in MRL/l mice. In addition, ulinastatin significantly inhibited human granulocyte elastase and cathepsin G. These findings indicate that ulinastatin may be a useful therapeutic agent for arthritis.
D000818:Animals; D000921:Antibody-Producing Cells; D007611:Aprotinin / Q000494:pharmacology; D001168:Arthritis / Q000000981:diagnostic imaging / Q000188:drug therapy*; D001169:Arthritis, Experimental / Q000000981:diagnostic imaging / Q000188:drug therapy; D002351:Carrageenan; D002358:Cartilage, Articular / Q000187:drug effects; D005260:Female; D016670:Gabexate; D006023:Glycoproteins / Q000494:pharmacology; D006146:Guanidines / Q000494:pharmacology; D007270:Injections, Intra-Articular; D007275:Injections, Intravenous; D008213:Lymphocyte Activation; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D008815:Mice, Inbred Strains; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011817:Rabbits; D011859:Radiography; D051381:Rats; D011919:Rats, Inbred Strains; D012217:Rheumatoid Factor / Q000032:analysis
D006023:Glycoproteins; D006146:Guanidines; D011480:Protease Inhibitors; D016670:Gabexate; D002351:Carrageenan; D012217:Rheumatoid Factor; D007611:Aprotinin; C028665:urinastatin